
Kaisa
Huhtinen
Project Specialist, Institute of Biomedicine
Adjunct Professor, Faculty of Medicine
PhD, Adjunct Professor in Cancer Biology
Areas of expertise
Ovarian cancer
personalized medicine
early diagnostics
prediction
prognosis
biomarker
genomics
drug target
interdicipline research;
Biography
2018 Starting as an independent group leader
2016 Adjunct Professor, Cancer Biology, University of Turku
2014 Cell biologist (4 months), Turku University Hospital
2012- Postdoctoral fellow / Senior researcher in Olli Carpén research group, Univ. Turku
2010-2012 Postdoctoral fellow in the ENDOMET study, Prof. Matti Poutanen group, Univ. Turku
2010 Ph.D., Departments of Physiology and Obstetrics & Gynecology, University of Turku
2016 Adjunct Professor, Cancer Biology, University of Turku
2014 Cell biologist (4 months), Turku University Hospital
2012- Postdoctoral fellow / Senior researcher in Olli Carpén research group, Univ. Turku
2010-2012 Postdoctoral fellow in the ENDOMET study, Prof. Matti Poutanen group, Univ. Turku
2010 Ph.D., Departments of Physiology and Obstetrics & Gynecology, University of Turku
Research
I am interested in understanding molecular mechanisms behind high-grade serous ovarian cancer, which is the most lethal type of epithelial ovarian cancer. Our reseach focuses on two main themes: genomic alterations such as gene fusions and development of innovative diagnostic tools. Our ultimate aim is to improve patient survival by 1) developing biomarkers / marker panels for early detection of HGSOC, 2) finding predictive markers enabling personalized therapies, and 3) characterizing new potential drug targets for personalized HGSOC treatment.
Publications
Ovarian Cancers with Low CIP2A Tumor Expression Constitute an APR-246-Sensitive Disease Subtype (2022)
Molecular Cancer Therapeutics
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))
Dubious effects of methadone as an “anticancer” drug on ovarian cancer cell-lines and patient-derived tumor-spheroids (2022)
Gynecologic Oncology
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))
QuantISH: RNA in situ hybridization image analysis framework for quantifying cell type-specific target RNA expression and variability (2022)
Laboratory Investigation
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))
Effects of Wee1 inhibitor adavosertib on patient-derived high-grade serous ovarian cancer cells are multiple and independent of homologous recombination status (2022)
Frontiers in Oncology
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))
Diagnostic potential of nanoparticle aided assays for MUC16 and MUC1 glycovariants in ovarian cancer (2022)
International Journal of Cancer
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))
Longitudinal single-cell RNA-seq analysis reveals stress-promoted chemoresistance in metastatic ovarian cancer (2022)
Science Advances
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))
FUNGI: Fusion Gene Integration Toolset (2021)
Bioinformatics
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))
Aggressive and recurrent ovarian cancers upregulate ephrinA5, a non-canonical effector of EphA2 signaling duality (2021)
Scientific Reports
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))
Network-guided identification of cancer-selective combinatorial therapies in ovarian cancer (2021)
Briefings in Bioinformatics
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))
Targeting DNA Homologous Repair Proficiency With Concomitant Topoisomerase II and c-Abl Inhibition (2021)
Frontiers in Oncology
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))